This week, an op-ed by John C. Lechleiter - the president, chairman and CEO of Eli Lilly and Company, one of PhRMA's member companies - highlighted what he calls "two success stories," one being the jobs supported in Indiana by the innovative life sciences sector there and the other being the "efficiency and satisfaction" associated with Medicare Part D, the prescription drug benefit.
Most Recent Posts
Biotechnology medicines are developed through biological processes using living cells or organisms, rather than the traditional chemical synthesis approach. The biotechnology medicines in the new report "Biotechnology Medicines in Development," are targeting autoimmune diseases, cancer, cardiovascular diseases, diabetes, HIV/AIDS and other infectious diseases, psoriasis, Alzheimer's disease, Parkinson's disease, asthma, chronic obstructive pulmonary disease; hemophilia, glaucoma and many genetic disorders.
I remember one newspaper column from nearly a year ago that has stuck with me: a physician boasting about his refusal to engage with biopharmaceutical research companies. He was proud of his decision, but he went so far as to confess that he doesn't always know about new medicines reaching the market.
I wonder how the patients he treated would have felt to hear that.
Take a look at Thomas Capone's oped "Medicare D Change N.J. Can Ill Afford" at NorthJersey.com. It does a good job at putting the potential consequences of proposed Medicare drug benefit changes into perspective.
Last week, we directed your attention to a settlement Google made with the Department of Justice, in which Google forfeited the money they'd made accepting ads from online Canadian pharmacies.
By opening America's doors to potential counterfeit prescription medicines, this practice put patients in the U.S. in danger.
Just over 30 years ago was the first time that a medical journal mentioned the disease we now know as HIV/AIDS. Just three years later, researcher Marty St.
Since launching The Catalyst earlier this year, we've covered a number of economic, health and policy issues that, regardless of outcome, stand to impact millions worldwide. In our first post, we made the point that none of us have all the answers, which makes it especially critical that we hear from a range of experts, thought leaders and Catalyst readers to get to the bottom of key issues.